Company profile

MacroGenics

MGNX · NASDAQ

Share price · MGNX

$4.09-0.26 (-5.98%) 3M

close as of 2026-08-18 · 24h delayed · vol 430K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 1
ADAM9Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
HIV envelope gp120 x CD3Multispecific antibody
HIV
Phase 1
HIV envelope gp41 x CD3Multispecific antibody
HIV
Phase 1
CD123 x CD3Multispecific antibody
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.